Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated Receptorα Helix 12 Dynamic Behavior*
暂无分享,去创建一个
Aurélien Grosdidier | Olivier Michielin | Vincent Zoete | Béatrice Desvergne | W. Wahli | V. Zoete | O. Michielin | L. Michalik | J. Feige | L. Gelman | B. Desvergne | Walter Wahli | A. Grosdidier | G. Krey | Liliane Michalik | Pierre Chodanowski | Jérôme N Feige | Laurent Gelman | Grigorios Krey | Pierre Chodanowski
[1] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] Markus Meuwly,et al. Study of the insulin dimerization: Binding free energy calculations and per‐residue free energy decomposition , 2005, Proteins.
[3] Ping-Chiang Lyu,et al. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. , 2007, Journal of medicinal chemistry.
[4] W. Wahli,et al. PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents , 1997, Biological chemistry.
[5] J. Auwerx,et al. p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* , 1999, The Journal of Biological Chemistry.
[6] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[7] D. Case,et al. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.
[8] Hoover,et al. Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.
[9] M. Karplus,et al. Simulation of activation free energies in molecular systems , 1996 .
[10] W. Wahli,et al. Involvement of PPAR nuclear receptors in tissue injury and wound repair. , 2006, The Journal of clinical investigation.
[11] T. Willson,et al. Peroxisome proliferator activated receptor agonists. , 1997, EXS.
[12] J. Schwabe,et al. Mechanism of the nuclear receptor molecular switch. , 2004, Trends in biochemical sciences.
[13] Terry K. Smith,et al. Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.
[14] José M Bautista,et al. Three Peroxisome Proliferator-activated Receptor Isotypes from Each of Two Species of Marine Fish , 2022 .
[15] N. Blomberg,et al. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .
[16] V. Chatterjee,et al. Functional analysis of a transactivation domain in the thyroid hormone beta receptor. , 1994, The Journal of biological chemistry.
[17] R. DesJarlais,et al. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere. , 1994, Journal of medicinal chemistry.
[18] L. Jendeberg,et al. Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.
[19] Olivier Poch,et al. Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level , 2004, EMBO reports.
[20] P E Bourne,et al. The Protein Data Bank. , 2002, Nucleic acids research.
[21] D. Moras,et al. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. , 2002, Molecular cell.
[22] Bin He,et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.
[23] Hans Peter Märki,et al. Structure-based design of indole propionic acids as novel PPARα/γ co-agonists , 2006 .
[24] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[25] Satoshi Yasuda,et al. Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.
[26] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[27] W. C. Still,et al. A rapid approximation to the solvent accessible surface areas of atoms , 1988 .
[28] Xiaohong Liu,et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors , 2003, Nature.
[29] William Bourguet,et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.
[30] C. Carlberg,et al. The critical role of carboxy-terminal amino acids in ligand-dependent and -independent transactivation of the constitutive androstane receptor. , 2003, Molecular endocrinology.
[31] T. Halgren. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .
[32] B. M. Forman,et al. A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity , 2002, Molecular and Cellular Biology.
[33] J. Girard,et al. Phosphorylation of PPARs: from molecular characterization to physiological relevance. , 2005, Biochimie.
[34] M. Lazar,et al. A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.
[35] Charles L. Brooks,et al. Generalized born model with a simple smoothing function , 2003, J. Comput. Chem..
[36] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[37] B. Brooks,et al. Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .
[38] Béatrice Desvergne,et al. Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.
[39] J. Schwabe,et al. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.
[40] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[41] Kendall W Nettles,et al. Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.
[42] Peter J. Brown,et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .
[43] J. Lehmann,et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.
[44] Charles L. Brooks,et al. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..
[45] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[46] C. Carlberg,et al. Agonist-dependent and Agonist-independent Transactivations of the Human Constitutive Androstane Receptor Are Modulated by Specific Amino Acid Pairs* , 2004, Journal of Biological Chemistry.
[47] Jean-Paul Renaud,et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.
[48] I. Lu,et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.
[49] D. Moore,et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements , 1994, Molecular and cellular biology.
[50] Samuel H. Yalkowsky,et al. Solubility of nonelectrolytes in polar solvents. V. Estimation of the solubility of aliphatic monofunctional compounds in water using a molecular surface area approach , 1975 .
[51] M. Lazar,et al. Interdomain communication regulating ligand binding by PPAR-γ , 1998, Nature.
[52] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[53] J. Berger,et al. PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.
[54] W. Wahli,et al. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.
[55] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[56] Christine Dreyer,et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.
[57] Thomas A. Kunkel,et al. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[58] D. Waxman,et al. STAT5b Down-regulates Peroxisome Proliferator-activated Receptor α Transcription by Inhibition of Ligand-independent Activation Function Region-1trans-Activation Domain* , 1999, The Journal of Biological Chemistry.
[59] D. Barettino,et al. Characterization of the ligand‐dependent transactivation domain of thyroid hormone receptor. , 1994, The EMBO journal.
[60] E. Purisima,et al. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. , 2006, Human molecular genetics.
[61] R G Smith,et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.
[62] Terry K. Smith,et al. Reevaluation of the PPAR-β/δ Ligand Binding Domain Model Reveals Why It Exhibits the Activated Form , 2006 .
[63] P. Kushner,et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.
[64] Béatrice Desvergne,et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.
[65] Robert B. Hermann,et al. Theory of hydrophobic bonding. II. Correlation of hydrocarbon solubility in water with solvent cavity surface area , 1972 .
[66] C. Carlberg,et al. Structural Determinants of the Agonist-independent Association of Human Peroxisome Proliferator-activated Receptors with Coactivators* , 2005, Journal of Biological Chemistry.
[67] Markus Meuwly,et al. Importance of individual side chains for the stability of a protein fold: Computational alanine scanning of the insulin monomer , 2006, J. Comput. Chem..
[68] A. Burger,et al. Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor α by Phosphorylation of a Ligand-independent trans-Activating Domain* , 1999, The Journal of Biological Chemistry.
[69] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[70] K. Umesono,et al. A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.
[71] P. Chambon,et al. Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.
[72] W. Wahli,et al. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. , 2005, Current opinion in cell biology.
[73] C. Brooks,et al. Novel generalized Born methods , 2002 .
[74] Thomas A. Halgren,et al. Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .
[75] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[76] D. Moras,et al. Structural studies on nuclear receptors , 2000, Cellular and Molecular Life Sciences CMLS.
[77] P. Chambon,et al. Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. , 1997, Genes & development.
[78] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[79] Kaixian Chen,et al. Binding analyses between Human PPARgamma-LBD and ligands. , 2004, European journal of biochemistry.
[80] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[81] Thomas A. Halgren,et al. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..
[82] T. Halgren,et al. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .
[83] Y. Kong,et al. Dynamic inhibition of nuclear receptor activation by corepressor binding. , 2003, Molecular endocrinology.